New Zealand Direct-to-Patient Market: By Type (DTP Marketing, DTP Health Services, DTP Clinical Trials, and DTP Logistics), By Therapeutics (Respiratory Diseases, Oncology, Infectious Diseases, Dermatology, and Other Therapeutics), By Model (Site-to-Patient, Hybrid Model, Direct-From-Patient (DfP), and Other DtP Models), and Country Forecast 2021-2032

New Zealand Direct-to-Patient Market size was valued at US$ X million in 2025 and is expected to reach US$ X million by 2032, growing at a significant CAGR of X% from 2026-2032. The DTP market relates to the concept of the distribution model of pharmaceuticals, healthcare devices, or medical services directly to the patient without the interface between traditional channels, e.g., a pharmacy or a healthcare professional. That usually includes either an online platform, a platform offering telehealth services, or some sort of specialized logistics network to ensure that the patient gets their medicines or medicinal products right at the comfort of their homes. The DTP model has gained increased favor as there is a growing need for convenience, especially in the management of chronic diseases, remote areas, and during situations like the COVID-19 pandemic.

In New Zealand, the Direct-to-Patient market has been growing steadily, driven by an aging population, increased prevalence of chronic diseases, and advancements in digital health technologies. For instance, as per the article published in the gerontologist over the next 20 years, the older population in New Zealand is predicted to double to 1.30 million due to ongoing increases in life expectancy. Additionally, the integration of telemedicine with DTP services can enhance patient engagement and adherence to treatment plans, creating new opportunities for market growth. However, the DTP model faces regulatory hurdles, particularly around the direct delivery of prescription medications and the need to comply with stringent pharmaceutical regulations.

Key Developments

• In 2023, 2023, CarePlus introduced a system that monitors patient medication adherence through AI, sending reminders and alerts directly to patients' smartphones. This development has improved patient outcomes and increased the appeal of DTP services among chronically ill patients who require consistent medication management.
• In 2022, Medplus, a healthcare provider, introduced an app that enables patients to order repeat prescriptions and have them delivered directly to their homes.